Data from Ph 1/2 trial of Multi-Antigen Targeted T cells in patients with pancreatic cancer announced
“We congratulate the research team at Baylor College of Medicine on this outstanding work and encouraging results in patients with pancreatic cancer,” said Juan Vera, MD, President and CEO of Marker Therapeutics. “The data highlights the excellent safety profile of Multi-Antigen Targeted T cells and demonstrates that they can be used in combination with frontline chemotherapy. We believe that this clinical proof-of-concept study emphasizes the potential of Multi-Antigen Targeted T cells in pancreatic cancer and sets the stage for continued development toward addressing a critical unmet need.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo